Supernus Pharmaceuticals (NASDAQ:SUPN) PT Lowered to $42.00
Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) had its target price trimmed by Piper Sandler from $43.00 to $42.00 in a report published on Wednesday, Benzinga reports. The firm currently has an overweight rating on the specialty pharmaceutical company’s stock. Separately, StockNews.com upgraded shares of Supernus Pharmaceuticals from a hold rating to a buy rating in […]
More Stories
Natarajan Sethuraman Sells 1,409 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) insider Natarajan Sethuraman sold 1,409 shares of the firm’s stock in a...
JPMorgan Active Bond ETF (NYSEARCA:JBND) Shares Acquired by Vawter Financial Ltd.
Vawter Financial Ltd. lifted its position in JPMorgan Active Bond ETF (NYSEARCA:JBND – Free Report) by 98.5% during the 3rd...
Coastline Trust Co Has $5.94 Million Stock Position in Uber Technologies, Inc. (NYSE:UBER)
Coastline Trust Co raised its position in Uber Technologies, Inc. (NYSE:UBER – Free Report) by 13.5% in the third quarter,...
Cornercap Investment Counsel Inc. Has $646,000 Holdings in Progress Software Co. (NASDAQ:PRGS)
Cornercap Investment Counsel Inc. decreased its holdings in shares of Progress Software Co. (NASDAQ:PRGS – Free Report) by 59.0% in...
Cornercap Investment Counsel Inc. Reduces Holdings in Genpact Limited (NYSE:G)
Cornercap Investment Counsel Inc. trimmed its holdings in Genpact Limited (NYSE:G – Free Report) by 50.5% during the third quarter,...
Cornercap Investment Counsel Inc. Sells 29,892 Shares of Universal Insurance Holdings, Inc. (NYSE:UVE)
Cornercap Investment Counsel Inc. lowered its stake in Universal Insurance Holdings, Inc. (NYSE:UVE – Free Report) by 52.9% during the...